Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073260 | 1.00 | MITF (0.39) | MITFMEN1KMT2AHDAC9KIF11 | |
| SCHEMBL2523832 | 0.83 | SIGMAR1 (0.39) | KMT2AHDAC9KIF11SLC6A4 | |
| SCHEMBL2525394 | 0.83 | SIGMAR1 (0.39) | KMT2AHDAC9KIF11SLC6A4 | |
| SCHEMBL28703383 | 0.78 | SIGMAR1 (0.39) | MEN1KMT2A | |
| SCHEMBL15355355 | 0.76 | ALDH1A1 (0.43) | MEN1KMT2AHDAC9 | |
| SCHEMBL9375293 | 0.75 | SIGMAR1 (0.46) | MEN1KMT2A | |
| SCHEMBL15355309 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AHDAC9 | |
| SCHEMBL15355348 | 0.73 | MEN1 (0.39) | MEN1KMT2AHDAC9POLB | |
| SCHEMBL1724164 | 0.71 | SIGMAR1 (0.38) | KIF11OPRM1OPRD1OPRK1 | |
| SCHEMBL22776858 | 0.70 | CHRM5 (0.34) | MEN1KMT2AHDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291374-A1 | PROCESS FOR PREPARATION OF SOLIFENACIN AND/OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF OF HIGH PHARMACEUTICAL PURITY | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009139002-A3 | AN IMPROVED PROCESS FOR THE PREPARATION OF SOLIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| US-20090326230-A1 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-12-31 | — | — | US | disclosed |
| WO-2009139002-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF SOLIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139002-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF SOLIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2009-11-19 | — | — | WO | disclosed |
| EP-2046751-A2 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008011462-A2 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326230-A1 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | OPRL1, ADRA1A, OPRK1 | MITF 3881/4885MEN1 1885/4885KMT2A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.